Table 1. Clinicopathological characteristics and univariate association by histology.
| Covariate | Gastric squamous cell carcinoma (n=836) | Gastric adenosquamous carcinoma (n=327) | Gastric adenocarcinoma (n=60,052) | Parametric P value* |
|---|---|---|---|---|
| Race, n (Col %) | <0.001 | |||
| White | 586 (70.1) | 267 (81.7) | 46,545 (77.5) | |
| Black | 203 (24.3) | 41 (12.5) | 8,655 (14.4) | |
| Others/unknown | 47 (5.6) | 19 (5.8) | 4,852 (8.1) | |
| Sex, n (Col %) | 0.003 | |||
| Male | 606 (72.5) | 245 (74.9) | 41,227 (68.7) | |
| Female | 230 (27.5) | 82 (25.1) | 18,825 (31.3) | |
| Age at diagnosis, n (Col %) | 0.005 | |||
| Mean | 65.9 | 66.5 | 67.4 | |
| Min | 23 | 22 | 18 | |
| Max | 90 | 90 | 90 | |
| SD | 12.1 | 11.9 | 13.3 | |
| Year of diagnosis, n (Col %) | 0.008 | |||
| 2004–2008 | 367 (43.9) | 139 (42.5) | 28,854 (48.0) | |
| 2009–2013 | 469 (56.1) | 188 (57.5) | 31,198 (52.0) | |
| Primary site, n (Col %) | <0.001 | |||
| C160- Cardia, NOS | 711 (85.0) | 213 (65.1) | 27,594 (46.0) | |
| C161- Fundus of stomach | 29 (3.5) | 16 (4.9) | 1,980 (3.3) | |
| C162- Body of stomach | 11 (1.3) | 12 (3.7) | 3,590 (6.0) | |
| C163- Gastric of stomach | 10 (1.2) | 25 (7.6) | 8,330 (13.9) | |
| C164- Pylorus | 1 (0.1) | 3 (0.9) | 1,285 (2.1) | |
| C165- Lesser curvature of stomach, NOS | 11 (1.3) | 13 (4.0) | 3,497 (5.8) | |
| C166- Greater curvature of stomach, NOS | 3 (0.4) | 6 (1.8) | 1,613 (2.7) | |
| C168- Overlapping lesion of stomach | 17 (2.0) | 16 (4.9) | 3,170 (5.3) | |
| C169- Stomach, NOS | 43 (5.1) | 23 (7.0) | 8,393 (14.0) | |
| AJCC clinical T, n (Col %) | <0.001 | |||
| 0 | 0 (0) | 2 (0.6) | 139 (0.2) | |
| 1 | 89 (10.6) | 25 (7.6) | 7,706 (12.8) | |
| 2 | 65 (7.8) | 30 (9.2) | 5,930 (9.9) | |
| 3 | 229 (27.4) | 77 (23.5) | 11,846 (19.7) | |
| 4 | 102 (12.2) | 43 (13.1) | 5,794 (9.6) | |
| IS | 0 (0) | 0 (0) | 200 (0.3) | |
| Unknown | 351 (42.0) | 150 (45.9) | 28,437 (47.4) | |
| AJCC Clinical N, n (Col %) | <0.001 | |||
| 0 | 264 (31.6) | 95 (29.1) | 19,206 (32.0) | |
| 1 | 271 (32.4) | 97 (29.7) | 14,218 (23.7) | |
| 2 | 33 (3.9) | 15 (4.6) | 2,763 (4.6) | |
| 3 | 18 (2.2) | 5 (1.5) | 1,360 (2.3) | |
| Unknown | 250 (29.9) | 115 (35.2) | 22,505 (37.5) | |
| AJCC clinical M, n (Col %) | 0.032 | |||
| 0 | 504 (60.3) | 220 (67.3) | 39,727 (66.2) | |
| 1 | 289 (34.6) | 93 (28.4) | 17,971 (29.9) | |
| Unknown | 43 (5.1) | 14 (4.3) | 2,354 (3.9) | |
| AJCC Analytic Stage Group, n (Col %) | <0.001 | |||
| Stage 0 | 8 (1.0) | 1 (0.3) | 337 (0.6) | |
| Stage I | 84 (10.0) | 38 (11.6) | 11,178 (18.6) | |
| Stage II | 124 (14.8) | 58 (17.7) | 8,154 (13.6) | |
| Stage III | 156 (18.7) | 78 (23.9) | 10,610 (17.7) | |
| Stage IV | 325 (38.9) | 124 (37.9) | 21,971 (36.6) | |
| Stage group unknown | 139 (16.6) | 28 (8.6) | 7,802 (13.0) | |
| Surgery at primary site, n (Col %) | <0.001 | |||
| No | 614 (73.4) | 149 (45.6) | 32,760 (54.6) | |
| Yes | 217 (26.0) | 178 (54.4) | 27,155 (45.2) | |
| Unknown | 5 (0.6) | 0 (0) | 137 (0.2) | |
| Surgical margin, n (Col %) | <0.001 | |||
| Negative | 184 (22.0) | 135 (41.3) | 22,255 (37.1) | |
| Positive | 17 (2.0) | 37 (11.3) | 3,656 (6.1) | |
| Unknown | 21 (2.5) | 6 (1.8) | 1,381 (2.3) | |
| No surgery | 614 (73.4) | 149 (45.6) | 32,760 (54.6) | |
| Histologic grade n (Col %) | <0.001 | |||
| Well differentiated | 49 (5.9) | 1 (0.3) | 2,712 (4.5) | |
| Moderately differentiated | 235 (28.1) | 52 (15.9) | 17,439 (29.0) | |
| Poorly differentiated/undifferentiated | 389 (46.5) | 223 (68.2) | 30,618 (51.0) | |
| Cell type not determined | 163 (19.5) | 51 (15.6) | 9,283 (15.5) | |
| Chemotherapy, n (Col %) | <0.001 | |||
| No | 314 (37.6) | 119 (36.4) | 26,859 (44.7) | |
| Yes | 500 (59.8) | 202 (61.8) | 31,477 (52.4) | |
| Unknown | 22 (2.6) | 6 (1.8) | 1,716 (2.9) | |
| Radiotherapy, n (Col %) | <0.001 | |||
| No | 425 (50.8) | 201 (61.5) | 40,581 (67.6) | |
| Yes | 402 (48.1) | 123 (37.6) | 18,985 (31.6) | |
| Unknown | 9 (1.1) | 3 (0.9) | 486 (0.8) | |
| Immunotherapy, n (Col %) | 0.448 | |||
| No | 826 (98.8) | 321 (98.2) | 59,160 (98.5) | |
| Yes | 1 (0.1) | 3 (0.9) | 312 (0.5) | |
| Unknown | 9 (1.1) | 3 (0.9) | 580 (1.0) | |
| Systemic/surgery sequence, n (Col %) | <0.001 | |||
| Systemic therapy before surgery | 94 (11.2) | 46 (14.1) | 5,347 (8.9) | |
| Systemic therapy after surgery | 24 (2.9) | 39 (11.9) | 5,718 (9.5) | |
| Systemic therapy before and after surgery | 6 (0.7) | 9 (2.8) | 1,080 (1.8) | |
| Intraoperative systemic therapy during surgical procedure | 0 (0) | 0 (0) | 8 (0.1) | |
| Intraoperative systemic therapy with other Rx administered before or after surgery | 0 (0) | 0 (0) | 10 (0.1) | |
| Sequence unknown | 162 (19.4) | 62 (19.0) | 12,386 (20.6) | |
| No systemic therapy and/or no surgery | 550 (65.8) | 171 (52.3) | 35,503 (59.1) | |
| Radiation surgery sequence at any CoC facility, n (Col %) | <0.001 | |||
| Radiation therapy before surgery | 105 (12.6) | 40 (12.3) | 4,682 (7.8) | |
| Radiation therapy after surgery | 28 (3.3) | 39 (11.9) | 5,497 (9.2) | |
| Radiation therapy both before and after surgery | 0 (0) | 2 (0.6) | 48 (0.1) | |
| Intraoperative radiation therapy | 0 (0) | 0 (0) | 1 (0) | |
| Intraoperative radiation therapy with other therapy administered before or after surgery | 0 (0) | 0 (0) | 4 (0) | |
| Sequence unknown | 18 (2.2) | 7 (2.1) | 1,015 (1.7) | |
| No radiation therapy and/or surgical procedures | 685 (81.9) | 239 (73.1) | 48,805 (81.3) |
*, the parametric P value is calculated by ANOVA for numerical covariates and Chi-square test for categorical covariates.